FDA Approves Obagi saypha ChIQ Injectable Hyaluronic Acid Gel for Cheek Augmentation
核心洞察
The FDA has approved Obagi saypha ChIQ, an injectable hyaluronic acid gel for cheek augmentation and correction of midface contour deficiencies in patients over 21.
The product utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix designed for natural-looking results with predictable injection force and swelling profiles.
Interim data from the ALOHA Program shows 94% of injectors believe the previously launched Obagi saypha MagIQ complements their current filler options.
Waldencast plc (搜索) (NASDAQ: WALD) announced on June 15, 2026 that the U.S. Food and Drug Administration has approved Obagi saypha ChIQ injectable hyaluronic acid (HA) gel, the latest addition to the Obagi Medical (搜索) injectable portfolio. The product is indicated for cheek augmentation and correction of midface contour deficiencies in patients over the age of 21.
The approval builds on the earlier launch of Obagi saypha MagIQ and accelerates Obagi Medical (搜索)'s strategy to establish itself as a comprehensive leader at the intersection of advanced skincare and medical aesthetics. The introduction of Obagi saypha ChIQ further expands the brand's addressable market in the fast-growing U.S. dermal filler category.
"Obagi saypha ChIQ is a meaningful addition to our integrated aesthetic portfolio – giving practitioners and patients more ways to achieve end-to-end skin transformation with predictable, measurable outcomes, and bringing us closer to our vision of building the world's leading dermatological megabrand," said Michel Brousset, Co-Founder and Chief Executive Officer of Waldencast.
MACRO Core Technology and Product Design
Obagi saypha ChIQ was developed by Croma-Pharma GmbH and utilizes proprietary MACRO Core Technology that creates a stable 3D HA matrix. According to the company, the technology is designed to provide natural-looking results with category-leading capabilities, including delivering high usable HA content at injection, consistent particle distribution, and predictable injection force and swelling profiles.
The product's high amount of crosslinked HA serves as a foundation for effectiveness and durability, as noted in supporting scientific literature. The saypha line has surpassed 130 million syringes produced globally, which Andreas Prinz, Chief Executive Officer of Croma-Pharma, highlighted as setting "a high standard for safety, quality, and patient satisfaction."
"We are thrilled to continue our successful partnership with Obagi Medical (搜索)," said Prinz. "Obagi saypha ChIQ brings meaningful innovation to the U.S. market."
ALOHA Program Interim Results
Obagi recently shared strong provider feedback from the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program, unveiled in January 2026. Designed to become the largest real-world evaluation of a newly launched HA filler to date, the program's interim data highlights that 94% of injectors believe Obagi saypha MagIQ complements their current filler options.
Notably, current industry data shows only 1 in 10 filler visits includes a professional skincare purchase, yet 42.6% of practices using Obagi saypha MagIQ have already evaluated Obagi skincare. This suggests the combination drives attachment rates well above the industry norm.
Dr. Carolyn Jacob, MD commented: "The approval of Obagi saypha ChIQ builds on the real-world success of Obagi saypha MagIQ and showcases Obagi's commitment to delivering clinically proven, high-performance integrated skincare plus injectable aesthetic solutions. This product strengthens our ability to address a wide range of patient needs with precision and confidence, while maintaining the highest standards of safety and efficacy."
Company Background
Obagi Medical (搜索) is an advanced skincare line with over 35 years of experience, initially known for its leadership in treating hyperpigmentation with the Obagi Nu-Derm System. The brand was the fastest-growing professional skincare brand in the U.S. in 2024 among the top 10 professional skin care brands, according to Kline's 2024 Global Professional Skin Care Series.
Croma-Pharma GmbH, founded in 1976 and headquartered near Vienna, Austria, is one of Europe's leading manufacturers of premium-quality HA syringes. The company employs approximately 400 people and makes its products available in over 80 countries. Its comprehensive aesthetics portfolio includes botulinum toxin, HA fillers, lifting threads, polynucleotide injectables, HA skin boosters, skincare, and autologous PRP medical devices. In 2026, Croma-Pharma is also re-entering the orthopedics market, marking a strategic expansion beyond aesthetics.